A randomized trial of mesenchymal stem cells in multiple system atrophy

@article{Lee2012ART,
  title={A randomized trial of mesenchymal stem cells in multiple system atrophy},
  author={Phil Hyu Lee and Ji Eun Lee and Han‐Soo Kim and Sook Keun Song and Hye Sun Lee and Hyo Suk Nam and June-Won Cheong and Yong Jeong and Hae-Jeong Park and Dong Joon Kim and Chung Mo Nam and Jong Doo Lee and Hyun Ok Kim and Young Ho Sohn},
  journal={Annals of Neurology},
  year={2012},
  volume={72}
}
OBJECTIVE Neuroprotective or regenerative strategies are invaluable in multiple system atrophy (MSA) due to its rapid progression with fatal prognosis. [...] Key MethodMETHODS Thirty-three patients with probable MSA-C and baseline unified MSA rating scale (UMSARS) scores ranging from 30 to 50 were randomly assigned to receive MSC (4 × 10(7) /injection) via intra-arterial and intravenous routes or placebo.Expand
Impact of Autologous Mesenchymal Stem Cell Infusion on Neuromyelitis Optica Spectrum Disorder: A Pilot, 2‐Year Observational Study
We evaluate safety and efficacy of autologous bone marrow‐derived mesenchymal stem cells (MSCs) as a potential treatment for neuromyelitis optica spectrum disorder (NMOSD).
Autologous mesenchymal stem cells: Hope for patients with multiple system atrophy?
TLDR
A small-scale interventional RCT of sequential intra-arterial and IV administration of mesenchymal stem cells in patients with cerebellar-type MSA found a small reduction in the increase of severity rating scores (Unified MSA Rating Scale [UMSARS]) over 1 year, as compared to placebo.
Cell-based therapeutic strategies for multiple sclerosis
TLDR
The status of cell-based therapies and consensus recommendations for future studies and clinical trials are summed up in Scolding et al.
Safety and Clinical Effects ofMesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in PatientsWith Amyotrophic Lateral Sclerosis Results of Phase 1 / 2 and 2 a Clinical Trials
IMPORTANCE Preclinical studies have shown that neurotrophic growth factors (NTFs) extend the survival of motor neurons in amyotrophic lateral sclerosis (ALS) and that the combined delivery of these
Mesenchymal Stromal Cells Perspective: New Potential Therapeutic for the Treatment of Neurological Diseases
TLDR
The present review aims to highlight the characteristics and basic research regarding the role of MSCs in neurological disease and to discuss the recent progress in clinical trials using M SCs to treat various neurological disorders.
A safety study on intrathecal delivery of autologous mesenchymal stromal cells in rabbits directly supporting Phase I human trials
TLDR
This preclinical study evaluated the safety of intrathecal autologous MSCs in a rabbit model and found them to be safe and effective in treating neurodegenerative diseases.
Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.
TLDR
The proposed MSC mechanisms of action in neurodegenerative diseases, which include growth factor secretion, exosome secretion, and attenuation of neuroinflammation are discussed.
Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial
We conducted a phase 1 clinical trial in nine patients with mild‐to‐moderate Alzheimer's disease to evaluate the safety and dose‐limiting toxicity of stereotactic brain injection of human umbilical
Mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis: signals for hope?
TLDR
It is expected that the above foundations, which have inspired this review, may result in the founding of an effective and/or palliative therapy for amyotrophic lateral sclerosis.
Towards translational therapies for multiple system atrophy
TLDR
This review summarizes the progress made in MSA research during the past decade by noting pre-motor features have gained relevance as early diagnostic markers and candidate α-synuclein lowering therapies have been explored in preclinical models.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
Mesenchymal Stem Cells in a Transgenic Mouse Model of Multiple System Atrophy: Immunomodulation and Neuroprotection
TLDR
The data suggest that intravenously infused Mesenchymal stem cells have a potent effect on immunomodulation and neuroprotection, and warrant further studies to elucidate the efficacy of systemically administered MSCs in transgenic MSA models.
Neuroprotective Effect of Human Mesenchymal Stem Cells in an Animal Model of Double Toxin-Induced Multiple System Atrophy Parkinsonism
TLDR
It is demonstrated that hMSC treatment protected against loss of neurons in the SN and the striatum induced by double toxin exposure, which may be mediated by modulation of inflammatory and cell survival and death signaling-pathway as the hMSCs migrated from the peripheral circulation into theSN and striatum.
Autologous Mesenchymal Stem Cell Therapy Delays the Progression of Neurological Deficits in Patients With Multiple System Atrophy
TLDR
It is demonstrated that MSC therapy in patients with MSA was safe and delayed the progression of neurological deficits with achievement of functional improvement in the follow‐up period.
Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson’s disease
TLDR
It is demonstrated that hMSCs treatment had a protective effect on progressive loss of dopaminergic neurons induced by MG‐132 in vitro and in vivo and complex mechanisms mediated by trophic effects of hMSC and differentiation of h MSCs into functional TH‐immunoreactive neurons may work in the neuroprotective process.
Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti‐inflammatory action
TLDR
HMSC treatment in rats showed that TH‐ip neuronal loss induced by LPS stimulation in the SN was considerably decreased and was clearly accompanied by a decrease in activation of microglia, as well as TNF‐α and iNOS mRNA expression and production of TNF-α.
Immunomodulatory properties of mesenchymal stromal cells.
TLDR
The aim of this review is to critically discuss the immunogenicity and immunomodulatory properties of MSCs, both in vitro and in vivo, the possible underlying mechanisms, the potential clinical use of M SCs as modulators of immune responses in vivo and to indicate clinical safety concerns and recommendations for future research.
Mesenchymal stem cells as trophic mediators
TLDR
Several studies which tested the use of MSCs in models of infarct (injured heart), stroke (brain), or meniscus regeneration models are reviewed within the context of M SC‐mediated trophic effects in tissue repair.
Mesenchymal Stem Cells for Ischemic Stroke: Changes in Effects after Ex Vivo Culturing
TLDR
The results indicate that ischemia-induced neurogenesis was enhanced by the IV administration of human MSCs, which may be related to the differential capacity in trophic support, depending on their passage.
Blood–brain barrier impairment is functionally correlated with clinical severity in patients of multiple system atrophy
TLDR
The data suggest that BBB dysfunction is related to the underlying nature of MSA and its dysfunction is closely coupled to disease severity.
Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy.
TLDR
The results indicate that combined mitochondrial inhibition and overexpression of oligodendroglial alpha-SYN generates a novel model of MSA that may be useful for evaluating both pathogenesis and treatment strategies.
...
1
2
3
4
...